---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024289"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:29:58.133897+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vivos Q3 revenue $6.8M (+78% seq, +76% YoY); operating loss widens to $4.7M

## Summary
- Revenue of $6.8M in Q3 2025, driven by first full quarter of Sleep Center of Nevada (SCN) acquisition; SCN added $2.2M diagnostic and $1.3M treatment revenue.
- Gross profit $3.9M (58% margin, down from 60% YoY); operating expenses $8.7M (+74% YoY) on SCN-related headcount and depreciation.
- Operating loss $4.7M ($2.6M in Q3 2024); cash $3.1M at Sept 30, 2025 vs $6.3M at Dec 31, 2024.
- Entered management agreement with MISleep Solutions for a joint location in Auburn Hills, MI, seeing patients from December; owns supermajority equity.
- Conference call at 5:00 pm ET; replay available until Dec 3, 2025.

## SEC filing metadata
- accession: 0001493152-25-024289
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315225024289/0001493152-25-024289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315225024289/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024289
- JSON: https://secwatch.observer/filing/0001493152-25-024289.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.